Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03238027
Title A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syndax Pharmaceuticals

Advanced Solid Tumor



Durvalumab + SNDX-6352

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.